CapsoVision Q1 Revenue Flat at $2.8M; AI Feature FDA Clearance Expected
CapsoVision’s first-quarter revenue held at $2.8 million while gross profit dropped 11% to $1.3 million as operating expenses rose $1.5 million. The company raised $14 million in equity financing and expects FDA clearance of its AI-assisted CapsoCam Plus reading feature mid-year, serving 167,000 patients.
1. First-Quarter Financial Performance
CapsoVision reported $2.8 million in first-quarter revenue, unchanged year-over-year, with gross profit of $1.3 million, an 11% decline from $1.5 million, and a gross margin of 48% versus 54% a year ago. Operating expenses rose to $8.4 million, up $1.5 million, driven by development of CMOS image sensors and clinical trial activities.
2. Pipeline and Regulatory Milestones
The AI-assisted reading feature for CapsoCam Plus is on track for FDA clearance by mid-year, positioning the company for enhanced end-user workflow. The second-generation CapsoCam Colon capsule is slated for 510(k) submission in Q3 2026, and a clinical study for CapsoCam UGI in pancreatic cancer detection began with its first patient enrolled in May 2026.
3. Financing and Cash Position
On March 16, CapsoVision closed a $14 million private placement of public equity, bolstering its cash and cash equivalents to $17.9 million as of March 31. This liquidity supports ongoing R&D, regulatory filings, and commercial expansion of its capsule endoscopy platform.
4. Customer Adoption and Renewals
Clinical adoption of CapsoCam Plus expanded, with over 167,000 patients served as of March 31, 2026. Key renewals were secured with Indiana University Health Systems, Providence Health Systems, and Gastro Health, reinforcing long-term customer relationships and platform value.